FDA approves AbbVie’s JUVMO for adults with Parkinson’s disease

ABBV•2026-09-28

The FDA cleared AbbVie’s JUVMO tablets for adults with Parkinson’s disease, making it the first selective D1/D5 receptor agonist in the US. AbbVie expects US availability in October 2026.

FDA approves AbbVie’s JUVMO for adults with Parkinson’s disease

1. Approval and dosing

Related News

Draganfly rises after $10 million stock deal with Trump Jr.-backed Unusual Machines, U.S. fund

Silicon Valley Acquisition amends EigenQ deal to swap certain company warrants for PubCo warrants at closing

Northern Star rejects Gold Fields' $27 billion bid to create world's No. 2 gold miner

Carlsmed names Richard Heppenstall CFO, succeeding Leo Greenstein

Powell Max signs deal to buy stake in Remington Firearms parent Blackrod Holdings